- Home
- WLII vs ANTX Comparison
WLII vs ANTX Comparison
Compare WLII & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WLII | ANTX |
|---|---|---|
| Founded | 2025 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.1M | 172.9M |
| IPO Year | 2026 | 2022 |
Fundamental Metrics
Financial Performance| Metric | WLII | ANTX |
|---|---|---|
| Price | $10.19 | $4.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 32.6K | ★ 242.7K |
| Earning Date | N/A | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.16 | $1.00 |
| 52 Week High | $10.29 | $7.19 |
Technical Indicators
Market Signals| Indicator | WLII | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 38.97 | 33.78 |
| Support Level | N/A | $3.91 |
| Resistance Level | $10.29 | $5.21 |
| Average True Range (ATR) | 0.01 | 0.41 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 0.00 | 13.29 |
Price Performance
Historical ComparisonAbout WLII Willow Lane Acquisition Corp. II Class A Ordinary Shares
Willow Lane Acquisition Corp II is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.